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1. Introduction
Although gastrointestinal endoscopy is generally safe, its safety must be separately analyzed
during pregnancy. Though it is prudent to postpone the investigation to the third trimester or
rather to the postpartum period; in certain clinical situations where therapeutic intervention is
necessary, it offers a relatively safe alternative to radiologic or surgical intervention. There are
a number of potential risks associated with endoscopy during pregnancy [1]:
1. Oversedation may cause maternal hypotension and hypoxia, which in turn may lead to
fetal hypoxia, with potentially fatal consequences.
2. The fetus may be exposed to potentially teratogenic drugs and radiaton.
3. Care must be taken with maternal positioning to avoid inferior vena caval compression by
the pregnant uterus, which can lead to decreased uterine blood flow and fetal hypoxia.
The American Society for Gastrointestinal Endoscopy (ASGE) guidelines [2] list the follow‐
ing general principles guiding endoscopy in pregnancy (Table1).
Fetal risks from endoscopic medications are minimized by avoiding FDA category D drugs,
minimizing endoscopic medications, and anesthesiologist attendance at endoscopy. Esopha‐
gogastroduedenoscopy (EGD) seems to be relatively safe for the fetus and may be per‐
formed when strongly indicated during pregnancy. Flexible sigmoidoscopy during
pregnancy also appears to be relatively safe for the fetus and may be performed when
strongly indicated. Colonoscopy may be considered in pregnant patients during the second
trimester if there is a strong indication. Data on colonoscopy during the other trimesters are
limited. Therapeutic endoscopic retrograde cholangiopancreatography (ERCP) seems to be
relatively safe during pregnancy and should be performed for strong indications (for exam‐
ple, complicated choledocholithiasis). Endoscopic safety precautions during pregnancy in‐
clude the performance of endoscopy in hospital by an expert endoscopist and only when
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strongly indicated, deferral of endoscopy to the second trimester whenever possible, and ob‐
stetric consultation.
1 Always have a strong indication, particularly in high-risk pregnancies
2 Defer endoscopy to second trimester whenever possible
3 Use lowest effective dose of sedative medications
4 Whenever possible, use category A or B drugs
5 Minimize procedure time
6 Position pregnant patients in left pelvic tilt or left lateral position to avoid vena cava or aortic compression
7 Presence of fetal heart sounds should be confirmed before sedation is begun and after the endoscopic
procedure
8 Obstetric support should be available in the event of a pregnancy-related complication
9 Endoscopy is contraindicated in obstetric complications such as placental abruption, imminent delivery, ruptured
membranes, or eclampsia
Table 1. General Principles guiding endoscopy in pregnancy (ASGE)
2. Fetal safety of endoscopic medications
One of the most important point in endoscopic procedures of pregnant patients is to avoid
maternal hypoxia and hypotension which can cause placental hypoperfusion and potential
fetal injury. Maternal oversedation with resulting hypoventilation or hypotension, or mater‐
nal positioning that might lead to inferior vena caval compression by the gravid uterus can
lead to decreased uterine blood flow and fetal hypoxia. Other potential risks to the fetus in‐
clude teratogenesis (both from medication given to the mother and radiation exposure from
fluoroscopy) and premature birth [1-6]. To prevent hypoxia and hypotension during the in‐
tervention, pregnant patients should be positioned in the left lateral position, prompt intra‐
venous hydration with normal saline or a similarly high osmolar solution should be made,
use of analgesics and sedatives should be restricted if possible and in the case of necessity
abortion of the endoscopic procedure should be considered [5,6].
Sedation in pregnancy has always been a challenge to anesthesiologists. No anesthetic drug,
inhaled anesthetics, or local anesthetic has been proven to be teratogenic in humans. A nota‐
ble exception is benzodiazepine group, which has been linked to congenital anomalies. All
agents that are administered during pregnancy must be used with caution and vigilence. It
is clear that anesthetic effects on placental perfusion and the placental transfer of depressant
drugs may influence the fetus [5,6,7].
During the endoscopic procedures in pregnant patients, anesthesiologic asistance is recom‐
mended in the first and third trimester because of the increaed risk of teratogenecity and the
risk of premature labor, respectively [5].
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The US Food and Drug Administration (FDA) lists 5 categories of drugs with regard to safe‐
ty during pregnancy [8] (Table 2).
Category Risk Description
A Controlled
studies show
no risk
Adequate, well-controlled studies in pregnant women have failed to demonstrate a risk
to the fetus in any trimester of pregnancy
B No evidence of
risk in humans
Adequate, well-controlled studies in pregnant women have not shown increased risk of
fetal abnormalities despite adverse findings in animals or, in the absence of adequate
human studies, animal studies show no fetal risk. The chance of fetal harm is remote,
but remains a possibility
C Risk cannot be
ruled out
Adequate, well-controlled human studies are lacking, and animal studies have shown a
risk to the fetus or are lacking as well. There is a chance of fetal harm if the drug is
administered during pregnancy, but the potential bene
fits may outweigh the potential risk
D Positive
evidence of risk
Studies in humans, or investigational or postmarketing data, have demonstrated fetal
risk. Nevertheless, potential benefits from the use of the drug may outweigh the
potential risk. For example, the drug may be acceptable if needed in a life-threatening
situation or for serious disease for which safer drugs cannot be used or are ineffective
X Contraindicate
d in pregnancy
Studies in animals or humans, or investigational or postmarketing reports, have
demonstrated positive evidence of fetal abnormalities or risk which clearly outweighs
any possible benefit to the patient
Table 2. FDA categorization of drug safety during pregnancy
This categorization indicates general risks based on four components: individual experimen‐
tal studies on drug risk in laboratory animals, number and quality of experimental studies,
individual clinical studies on drug risk in humans, and number and quality of clinical stud‐
ies. FDA categorization is, nonetheless useful in clinical practice. Category A drugs are safe
during pregnancy. Category B drugs may generally be used during pregnancy. Category C
drugs may often be used if required during pregnancy. Category D drugs are relatively con‐
traindicated, and when used should be administered with extreme caution. Category X
drugs are absolutely contraindicated during pregnancy [8].
There are no category A drugs used for endoscpy. For use during endoscopic procedures
category B and, when necessary, category C drugs are recommended. Category D drugs
may be used when benefits clearly outweigh the risks. These categories are of limited value
for determining the safety of one- time use; therefore, consultation with an obstetrician re‐
garding medication should be considered. For most procedures the level of sedation should
be anxiolysis or moderate sedation. İf deep sedation is necessary, it should be administered
by an anesthesiologist [2].
Key data on safety of commonly used endoscopic medications are summarized in table 3.
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Drug FDA category in
pregnancy
key points regarding drug safety
Narcotics
Meperidine B, but D at term Repeated high dose and prolonged administration can cause respiratory depression
and seizures.
Fentanyl C In low doses it is safe.
Propofol B Generally suggested to be used in difficult to sedate and complicated clinical
situations.
General anesthetics
Ketamine B Human data is limited; animal data suggests prolonged usage is unsafe.
Sedatives
Diazepam D Some of congenital malformations and mental retardations are possibly associated
with diazepam usage so its usage is discouraged during pregnancy.
Midazolam D As a benzodiazepine member, its usage is restricted during pregnancy especially in
first trimester.
Reversal agents
Naloxone B It is probably safe and should be used only in respiratory depression, systemic
hypotension or unresponsiveness in a closely monitored pregnant after endoscopy.
Flumazenil C Its fetal risks are largely unknown, it should be given in small doses carefully.
Table 3. Safety of anesthetics commonly used in gastrointestinal endoscopy
Meperidine, an opiate analgesic, was commonly used for gastrointestinal endoscopy in the
general population, but has been replaced by short-acting analgesics due to theoretical con‐
cerns about toxicity, manifested as respiratory depression and seizures. Meperidine is rapid‐
ly transferred across the human placenta after intravenous administration, after that
metabolized to normeperidine which has a long half-life. Repeated high dose and prolonged
administration of meperidine can cause progressive accumulation of normeperidine, and
produce toxic effects of maternal respiratory depression and seizures. Meperidine is rated a
category B drug during pregnancy, but rated category D when used for prolonged periods
(>36 h) at high doses at term. Meperidine use should be limited to 50–75 mg during routine
endoscopy during pregnancy [4,5,9].
Fentanyl is a potent narcotic agonist with a rapid onset of action and a shorter patient recovery
time than meperidine. It is an FDA category C drug during pregnancy. It appears safe when
given in low doses (<125 mg) in patients undergoing endoscopy during pregnancy [2,4,5].
Benzodiazepines (diazepam and midazolam) are commonly administrated before gastroin‐
testinal endoscopy to reduce anxiety, induce brief amnesia, and produce muscle relaxation.
Prolonged use of diazepam during early pregnancy has been associated with cleft palate
malformations [4,11] but several large studies have not shown this association [12,13]. Some
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studies have raised possible associations between diazepam administration and mental re‐
tardation or neurologic defects,[14] cardiac defects [11] and Mobius syndrome (sixth and
seventh nerve palsies) [15]. Diazepam is rated a category D drug during pregnancy, because
of these potential associations its use during pregnancy is discouraged, particularly in the
first trimester. Clinical data concerning fetal safety of midazolam are limited; however, the
drug has not been associated with oral cleft palates. Administration of midazolam during
labor has been reported to transiently depress neonatal neurobehavioral responsiveness
[16,17]. Although rated a category D drug, since it has not been reported to be associated
with congenital abnormalities, midazolam is the preferred benzodiazepine when meperi‐
dine is inadequate. Due to a similar mechanism of action as diazepam, midazolam use
should be restricted during pregnancy, especially during the first trimester [1,2,4,5].
Propofol is increasingly used for anesthesia at endoscopy in the general population. It is
short –acting with a recovery period much shorter than with standard agents. However, as a
result of a relatively narrow therapeutic index (defined as a ratio given by average toxic
dose divided by average therapeutic dose) and the potential for respiratory depression
which can cause respiratory arrest and even death if improperly monitored, it is generally
administrated by anesthesiologists. Endoscopy socities have recommended the usage of this
agent for difficult to sedate and complicated clinical situations. Propofol is rated a category
B drug and it is considered relatively safe to use during pregnancy, although its safety dur‐
ing the first trimester is inadequately studied [4,5,18].
Ketamine is useful for endoscopy in patients who are expected to experience insufficient seda‐
tion from propofol. Like propofol, ketamine has a rapid onset of action and a short duration of
effect. Although rated a category B drug during pregnancy, ketamine carries the caveats that
fetal safety during the first trimester is unstudied and unknown in humans, and an extremely
high dose or prolonged administration of it during pregnancy may be unsafe [4,19].
Naloxone, a rapidly acting narcotic antagonist, crossing the placenta within 2 minutes of in‐
travenous administration, is occasionally administered during endoscopy to reverse narcotic
overdose [2,4,20]. The drug is rated a category B drug during pregnancy. It should only be
used in respiratory depression, systemic hypotension or unresponsiveness in a closely moni‐
tored setting during or after endoscopy. It should be administered during pregnancy in
small, graded doses titrated to the desired effect. It should not be routinely administered af‐
ter endoscopy during pregnancy,since one neonatal fatality has been attributed to its use
[21]. Naloxone is contraindicated in pregnant patients who are dependent on narcotics be‐
cause it can precipitate opiate withdrawal syndrome [22]. Flumazenil, a benzodiazepine an‐
tagonist, is used to reverse oversedation from benzodiazepines administered during
endoscopy. It is rated a category C drug during pregnancy. The drug should only be used to
reverse benzodiazepine overdose during pregnancy because its fetal risks are largely un‐
known, with only few case reports of use during pregnancy. Flumazenil overdose can cause
maternal seizures, particularly when administrated to patients who are chronically habituat‐
ed to benzodiazepines. This overdose can be prevented by careful and slow titration and ad‐
ministration of minimal dosage of benzodiazepines required for endoscopy. [4,19,20,23].
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3. Upper gastrointestinal endoscopy
Although it would be ideal to postpone all endoscopic procedures until after delivery, preg‐
nant patients can develop conditions that require urgent upper endoscopy. The most common
indications for EGD in pregnant patients are significant or continued gastrointestinal hemor‐
rhage, dysphagia and refractory nausea and vomiting (Table 4). In a multicenter retrospective
study of 83 pregnant women on safety and clinical efficacy of EGD in pregnant patients; endos‐
copy indications included gastrointestinal bleeding, abdominal pain and vomiting in decreas‐
ing order [24].  The Mallory-Weiss tear was an important cause of upper gastrointestinal
bleeding in 14% of patients, the peptic ulcer was also responsible for 14% of gastrointestinal
bleeding in those patients which is significantly lower than the reported frequencies in non
pregnant patients. The diagnostic yield for upper gastrointestinal bleeding was 95% and there
was no cases of premature labour or congenital fetal malformation. Labor was not induced in
any of the patients and 95% of the patients gave birth to healthy infants. The four fetal deaths in
the study were in all high risk patients and were unrelated to EGD. The mean Apgar scores of
live born infants were not significantly different than control groups.
In an other study conducted by Debby et al [25], 60 pregnant women underwent EGD for
recurrent and intractable nausea and vomiting in their first trimester. In that study only 11
patients had the upper gastrointestinal bleeding, the other majority had only intractable
nausea and vomiting. The diagnostic yield of EGD in those patients appeared higher for
gastrointestinal bleeding than for intractable vomiting but the difference was not statistically
significant. Since the endoscopic findings only minimally changed the clinical management
of patients with nausea and vomiting the authors suggested the necessity of EGD for upper
gastrointestinal bleeding but not nausea and vomiting or hyperemesis gravidarum. A
mailed survey of over 3000 members of the American College of Gastroenterology, which
included information over 73 upper endoscopies performed during pregnancy. Endoscopic
diagnoses from these procedures included esophagitis, gastritis, ulcers, Mallory-Weis tears
and normal findings in descending order. This survey reported no significant complications
adversly affecting pregnancy [26].
The relationship between hyperemesis gravidarum and Helicabacter Pylori (H.Pylori) infec‐
tion is estimated by Bagis et all, in their study, H Pylori infection was histologically demon‐
strated in 95% of pregnant patients with hyperemesis gravidarum and 50% of control
patients. In that study patients with hyperemesis gravidarum had more severe H. Pylori in‐
fection compared to controls with H.Pylori infection, as measured histologically by density
of bacterial infiltration. Authors suggested the usage of H.Pylori diagnostic tests to be part
of hyperemesis gravidarum investigation [27]. Upper gastrointestinal complaints, especially
nause and vomiting, are very common in pregnants. During pregnancy with the effect of
progesteron and estrogen and with a lesser effect of motilin hormone the lower esophageal
sphincter (LES) tone, gastric and intestinal motility decrease, causing gastroesophageal re‐
flux disease (GERD) symptoms. As pregnancy progresses, the frequency of and intensity of
GERD symptoms increase which is caused by gastrointestinal motility changes during preg‐
nancy and with a small contribution of physical effects of gravid uterus [28,29]. So as a con‐
clusion endoscopy is rarely helpful and rarely indicated for nausea and vomiting, or even
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hyperemesis gravidarum, during pregnancy. In the presence of significant upper gastroin‐
testinal bleeding or severe nause and vomiting accompanied by abdominal pain or refracto‐
ry to medical treatment or signs of gastroduedenal obstruction, EGD may be appropriate to
exclude significant peptic ulcer, gastric outlet obstruction or to treat bleeding site. According
to the results of studies endoscopically the pregnant women has lower rate of peptic ulcer
diseases but higher rate of reflux esophagitis compared to non pregnant patients, and the
diagnostic yield of EGD for upper gastrointestinal bleeding during pregnancy is similar to
that of EGD performed for the same indication in the general population of about 95% [30].
Acute nonvariceal upper GI bleeding (NVUGB) is a common clinical emergency leading to
50-160 hospitalizations per 100000 adults. Mortality may be as high as 10-14%, although this
appears to be decreasing in many countries [31]. Endoscopy for the nonvariceal upper GI
bleeding (NVUGB) allows assesment of the risk of rebleeding and enables therapeutic he‐
mostasis that reduces bleeding, the need for surgery, and mortality. The largest analysis of
pregnant women for NVUGB is conducted by Geoffrey et al [32] in a population based
study including 1210 pregnant women with NVUGB and 6050 nonpregnant women with
NVUGB. Mallory-Weis tear was the most common identified cause of NVUGB in pregnant
women, in contrast peptic ulcer diesase and gastritis were the predominant etiologies for
NVUGB in nonpregnant patients. Pregnant women were less likely to require blood transfu‐
sion and were less likely to present with hypovolemic shock compared to nonpregnant
women. EGD was performed substantially less frequently in pregnant women compared
with nonpregnant women. The proportion of EGD’s that led to therapeutic intervention was
similar between pregnant and nonpregnant women, 8.9% vs 7.2% respectively. The mean in‐
terval from admission to EGD was longer for pregnant women compared with nonpregnant
women. There were no in-hospital deaths among pregnant women with NVUGB, the pro‐
portions of pregnant and nonpegnant women requiring surgery for upper GI bleeding were
not statistically different. Average hospital lenght of stay was shorter among pregnant wom‐
en compared with nonpregnant women. Although the rates of maternal mortality and fetal
loss were well below 1% in both groups, fetal distress/complications were lower in the preg‐
nant group admitted with NVUGB, as was premature delivery. It can be concluded as; it is
quite appropriate to defer endoscopy in a significant proportion of cases, who remain hemo‐
dynamically stable with self-limited NVUGB.
The indications of endoscopy in pregnacy is shown in table 4 [2].
1 Significant or continued bleeding
2 Severe or refractory nausea and vomiting or abdominal pain
3 Dysphagia or odynophagia
4 Strong suspicion of colon mass
5 Severe diarrhea with negative evaluation
6 Biliary pancreatitis, choledocholithiasis, or cholangitis
7 Biliary or pancreatic ductal injury
Table 4. Indications for endoscopy in pregnancy (ASGE)
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4. Therapeutic endoscopy
4.1. Endoscopic hemostasis for variceal bleeding
Patients with cirrhosis are not likely to become pregnant due to endocrine and metabolic im‐
balances. On the other hand, women with non-cirrhotic portal hypertension have normal
fertility rates. The incidence of variceal bleeding during pregnancy may reach up to 45%
with a mortality rate of 18-50% The variceal bleeding frequently occurs during the last two
trimester of gestation. The possible explanation for the high severity of variceal bleeding in
pregnancy seems to be related to the increase in water retention and cardiac output, typical
of both pregnancy and cirrhosis. Women with esophageal varices or severe liver disease
should be advised, in case of planning the pregnancy, about the high risk of both variceal
bleeding and hepatic decompensation during pregnancy. Also patients who have esopha‐
geal varices should be informed about the benefits of β-adrenergic receptor antagonist ther‐
apy during pregnancy to reduce portal pressure.
Both endoscopic injectional sclerotheraphy (EIS) and endoscopic band ligation (EBL) either
prophylactic or urgent seem to be safe procedures during pregnancy. When bleeding is not
arrested endoscopically in cirrhotic patients, an emergency transjugular intrahepatic porto‐
systemic shunt (TIPS) is indicated, but data regarding pregnant cirrhotic women are scarce
[33-39]. Since there are only a few case reports regarding the treatment options for this clini‐
cal condition, the management of esophageal varices and their major life-threatining compli‐
cation – hemorhage during pregnancy is still under evaluation. In the early 80’s EIS was
generally accepted as the first line treatment procedure for bleeding esophageal varices. De‐
spite this fact, only few cases of EIS with conventional sclerosants (polidocanol, absolute al‐
chocol, sodium tetradecyl sulphate) were reported during pregnancy [36,38,39]. There are
no studies regarding the effect of the conventional sclerosants on the fetus published in the
literature, although the procedure is considered safe and effective to control active variceal
bleeding. Vasoactive drugs used to achieve hemostasis are contraindicated during pregnan‐
cy, since these (vasopressin and terlipressin) may induce labor or fetal malformations [36].
Recently EBL was reported as an effective treatment option for active variceal hemorrhage
as well as prophylaxis of this severe complication during pregnancy [36-39].
In early 90’s EBL has been proven effective in controlling active hemorrhage and in long
term prevention of recurrent bleeding. There are several case reports that describe successful
hemostasis without fetal complications [40,41]. When EBL is used there is no risk of migra‐
tion of a toxic substance to placenta. Studies of EBL versus EST in nonpregnant patients
have shown improved reduction in rebleeding and mortality with EBL [40,42]. But there are
no studies directly comparing EBL to EST in pregnant patients.
In a study conducted by Aggarwal et al, 17 patients with noncirrhotic portal hypertension
caused by extrahepatic portal vein obstruction or portal fibrosis, underwent EIS with either
absolute alcohol or sodium tetradecyl sulphate for acute variceal bleeding without compli‐
cations during pregnancy. In that retrospective analysis pregnancy outcomes included six
healthy full-term infants, two preterm deliveries, three stillbirths, one neonatal death, and
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five voluntary abortions. In that report two patients required EBL after failure of EIS to ob‐
literate esophageal varices [43].
In an another report 10 patients underwent EIS with absolute alcohol, 5 patients for active
variceal bleeding and another 5 patients for the profilaxis of variceal bleeding. Hemostasis
was achieved in 5 actively variceal bleeding patients. All 10 patients delivered healthy in‐
fants [44]. According to the reported studies as in the nonpregnant population, EBL seems to
be a reasonable option for acute variceal bleeding as well as for the profilaxis of variceal
bleeding. EIS could be a secondary choice for the acute variceal bleeding due to the probable
effects on fetal safety.
When the endoscopic and pharmacological theraphy fails; TIPS may be a rescue procedure
in pregnant women with recurrent and difficult-to treat variceal bleeding. Several papers
confirm the utility and efficacy of TIPS for variceal bleeding unresponsive to endoscopic and
pharmacological treatment, however since adequate controlled trials are lacking, it should
be limited to a selected group of patients. TIPS placement is associated with radiation expo‐
sure of both the patient and the medical staff, it usually requires prolonged fluoroscopy. In
the literature there is a few case of TIPS placement in pregnancy in which between 5.2 mSv
and 2.1 mGy fetal dose of radiation reported [35,45,46]. So pregnancy is not an absolute con‐
traindication for TIPS placement in the treatment of relapsing bleeding varices and may be a
rescue procedure when medical and endoscopic treatments have failed.
4.2. Endoscopic hemostasis for nonvariceal bleeding
Endoscopic hemostatic techniques for nonvariceal bleeding include injection therapy with
saline, with adrenaline, sclerosants, thrombin, fibrin, cyanoacrilate, ablative therapy with
thermocoagulation, electrocoagulation, photocoagulation, argon plasma coagulation, and
mechanical compression with hemoclips, detachable snares, graspers, or sutures [47]. In
spite of these numerous techniques, there are a few case reports on fetal safety of endoscopic
hemostasis for NVUGB. In those case reports adrenalin injection, thermocoagulation and
electrocoagulation was used for hemostasis. In only one of the pregnant patient the hemo‐
static procedures were unsuccesful so patient required surgery. The fetal outcomes were
healthy infants without fetal malformations [24,25,47,48,49].
Adrenalin is category C drug and can cause a decrease in uterine blood flow. Although
there is limited data of case reports, no advers events from adrenaline injection were report‐
ed, in this case the benefits (cessation of hemorhage, prevention of rebleeding) would seem
to outweigh the risks [1,2,29,50].
Amniotic fluid can conduct electrical current to the fetus. During the electrocoagulation the
grounding pad should be placed in such a position that the uterus is not between the electri‐
cal catheter and grounding pad. Bipolar electrocautery should be used to minimize the risk
of ‘stray’ currents going through the fetus. Electrocautery is relatively safe when used for
hemostasis[2]. Due to the limited data on hemostasis for nonvariceal bleeding in pregnant
patients, the therapeutic technique choice is based on expert opinion and generally made ac‐
cording to the results of clinical studies of nonpregnant patients.
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4.3. Percutaneous endoscopic gastrostomy
During pregnancy, optimal nutrition is essential in order to minimize maternal and neonatal
morbidity [51]. Nause and vomiting are seen in 80% of pregnancies but usually symptoms
are mild and self limited. In case of severe hyperemesis gravidarum with dehydration and
ketonuria, patients should be hospitalized and receive intravenous hydration and anti-emet‐
ic agents. When the hospitalization duration prolongs without oral intake then supportive
nutrition with enteral feeding or total parenteral nutrition should be considereed [29]. Long
term nasogastric feeding is limited by patient intolerability and nasal septal necrosis. Side
effects of long term total parental nutrition limit its usage during pregnancy[52]. Thus per‐
cutaneous endoscopic gastrostomy (PEG) becomes an important option for long term enter‐
al feeding. However, concerns about uterine damage, fetal injury, premature labor, and
infections have restricted the application of PEG tube placement in pregnant women. There
were no major complications with PEG tube placement in the several reported cases in the
literature [53-61]. PEG enteral nutritional support was provided for an average of 14 weeks
in the literature. During the pregnancy PEG tube placement is a feasible procedure for opti‐
mal enteral nutrition in the critical care setting. It is also feasible to perform PEG tube place‐
ment in the third trimester of pregnancy. A potential problem with PEG during pregnancy
is puncture of uterus or fetus instead of the stomach during transabdominal neddle inser‐
tion. This risk is reduced by demarcating the upper border of uterus before PEG by abdomi‐
nal ultrasonography and by inserting the PEG needle ≥5cm cephaled.
PEG tube placement should be reserved only for severe refractory cases where the nutrition
of the mother and the fetus is at risk. The pregnant should be informed about the risks of the
procedure and potential placental injury. If possible less invasive alternative techniques as
nasoenteric feeding tube or peripherally inserted catheter for parenteral nutrition should be
attempted if this is not succesful or is refused by the patient, PEG tube placement should be
considered.
4.4. Percutaneous endoscopic gastrojejunostomy
Percutaneous endoscopic gastrojejunostomy( PEGJ) is a feeding tube placement in to the je‐
jenum via a gastrostomy. This placement enables food to be delivered more distally to de‐
crease the sensation of nausea, vomiting and risk of aspiration. PEGJ indications are similar
to PEG indications with additional risk of aspiration. In case of refractory nause and vomit‐
ing in the presence of PEG tube feeding, PEG tube can be converted to PEGJ. There are only
few case reports of PEGJ for hyperemesis gravidarum and one patient with coma from mas‐
sive stroke [62-65]. As in the PEG, PEGJ can be considered in very severe hyperemesis gravi‐
darum refractory to medical treatment and the other noninvasive treatment modalities.
5. Sigmoidoscopy/ colonoscopy
Most pregnant patients are young, healthy women and the gestational period is only 40
weeks in duration, because of that; it is unusual for them to need flexible sigmoidoscopy or
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colonoscopy during pregnancy. Lower endoscopy should be avoided for weak indications
during pregnancy and should be deferred until after the first trimester, or if possible, until
the postpartum period [66].
Although flexible sigmoidoscopy will be sufficient for most pregnant women, colonoscopy
may be required when there is life-threatening colonic bleeding and when a cause has not
been established by sigmoidoscopy. In late pregnancy, patients should not be placed in the
decubitus or prone position during colonoscopy. External abdominal pressure should gener‐
ally be avoided; if pressure is required, it should be minimal and directed away from the
uterus.
All avilable evidence suggests that sigmoidoscopy is safe during pregnancy and the indica‐
tions include rectal bleeding, chronic diarrhea, abdominal pain and rectal pain. Guidelines
for colonoscopy in pregnancy are not readily available due to insufficient data, although
studies which have been done demonstrate safety and efficacy of the procedure provided
that obstetrical consultation and close monitoring take place. Colonoscopy is indicated for
suspected colon cancer, uncontrolled severe hemorrhage or when necessary before colonic
surgery in pregnant women as well as in general population [67,68].
The safety and efficacy of the flexible sigmoidoscopy during pregnancy has been studied in
one case-controlled study of 45 patients undergoing 48 sigmoidoscopies [69]. The most com‐
mon clinical indication was hematochezia in 29 patients, diarrhea was the indication in 10
patients and abdominal pain was in 4 patients. The most common sigmoidoscopic diagnosis
included reactivated or newly diagnosed inflamatory bowel disease, bleeding internal hem‐
orroids and other colitis. Among the 29 patients with hematochezia, 8 patients were de novo
diagnosis or flare of ulcerative colitis, 7 patients were de novo diagnosis or flare of Crohn’s
disease, 3 patients with acute proctosigmoitidis, 2 patients were bleeding internal hemor‐
rhoids, 1 patient was pseudomembraneous colitis, and 1 patient was sigmoid adenoma.
Hematochezia gave the highest diagnostic yield compared with the other clinical indica‐
tions. Excluding one unknown pregnancy outcome and four voluntary abortions, 38 (93%)
of 41 pregnant patients who underwent sigmoidoscopy delivered healthy infants, including
27 at term. The mean Apgar score of live-born infants in this study was not statistically dif‐
ferent from the mean national Apgar score of live born infants.
Therapeutic changes because of the sigmoidoscopic findings occured in 24 patients, includ‐
ing changing or instituting medication for inflamatory bowel disease in 15 patients, steroid
enemas for nonspesific proctitis in two patients, avoiding surgery in two patients, and hem‐
orrhoidal treatment in two patients.
Other than this study there are individual case reports of sigmoidoscopy performed during
pregnancy and a mailed survey study [26, 70-74]. Multiple case reports describing flexible
sigmoidoscopy in pregnant patients showed the safety of this procedure. In the mailed sur‐
vey study; after contacting 3300 gastroenterologists, their responses indicated that there
were no endoscopic complications in 13 pregnant women who underwent flexible sigmoi‐
doscopy. In addition all pregnancies resulted in healthy infants. Common themes among
these reports include a relatively high diagnostic yield of flexible sigmoidoscopy when per‐
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formed during pregnancy for strong indications, clinically important changes in therapy re‐
sulting from sigmoidoscopic diagnosis, a relatively high rate of favorable fetal outcomes,
poor fetal outcomes generally occuring only in very sick mothers and unrelated to sigmoi‐
doscopy etiologically or temporally, and a low rate of congenital anomalies.
Studies suggested that sigmoidoscopy during pregnancy does not induce labor or cause
congenital malformations, it is not contraindicated, and should be considered in medically
stable patients with important indications. Sigmoidoscopy should be performed with mater‐
nal monitoring by electrocardiography and pulse oximetry, after obstetrical consultation
and after medical stabilization. Medical stabilization may require blood transfusions and
supplemental oxygenation [4,66,68]. Sigmoidoscopy is not recommended during pregnancy
for indications of a change in bowel habits, abdominal pain, a family history of colon cancer,
and routine screening or surveillance. In these cases, sigmoidoscopy is best deferred until at
least 6 weeks postpartum [67, 68].
Little is known about the safety or otherwise of bowel cleansing agents during pregnancy.
Studies have shown that the systemic absorbtion of Polyethylene glycol is minimal and the
problems with abdominal bloating and gas are less common as compared to other laxatives
[75] But since polyethylene glycol solutions have not been studied during pregnancy, there‐
fore it is a category C drug during pregnancy. Sodium phosphate solutions (also category C)
may cause fluid and electrolyte disturbance, and therefore probably best avoided during
pregnancy. Also it was published that newborns were shown to manifest bone deminerali‐
zation and bone growth failure because of maternal phosphate overload [76], although a one
time use in pregnancy has not shown to be detrimental. Another consideration when using
phosphosoda preperations is the risk of phosphate nephropathy [77] which has been report‐
ed in selected cases. As for bowel preperation for flexible sigmoidoscopy, phosphate enemas
should be relatively safe, but have not been studied in pregnancy. Tap water enemas may be
sufficient. In a study [78] of the preference of gastroenterologist and obstetricians of bowel
cleansing agent for sigmoidoscopy and colonoscopy in the same hospital, it was shown that
50% of gastroenterologist prefer to use polyethylene glycol solutions and 50% avoid use of
fleet phosphosoda. Twent percent of obstetricians seem to prefer fleet phosphosoda, and
26% avoid polyethylene glycol solutions which is exact opposite of gastroenterologist. Both
groups prefer fleet enema the most (51%), while magnesium citrate is used least often (38%).
6. Colonoscopy
There are insufficient data regarding the safety of performing colonoscopy during pregnan‐
cy. The largest case control study of 20 patients [79]; there were 20 pregnant patients under‐
going colonoscopy and 20 pregnant controls who were matched for colonoscopy but who
did not undergo colonoscopy. Colonoscopy indications in the study patients included diar‐
rhea, hematochezia, bloody diarrhea, abdominal pain, and other reasons. Colonoscopy was
performed in the second trimester in the majority of patients (n=16) with only 4 patients un‐
dergoing the procedure in the first and third trimester. Colonoscopic diagnoses were; ulcer‐
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ative colitis, ischemic colitis, Crohns colitis, and lymphocytic colitis. Colonoscopy led to
significant therapeutic changes in 7 (35%) patients. Two mothers experienced minor colono‐
scopic complications of mild, transient hypotension. Study patients had relatively favorable
fetal outcomes: 18 relatively healthy infants, 1 involuntary abortion, and 1 infant born with a
congenital defect (septum secundum cardiac defect).
In a mailed survey of 3300 gastroenterologists 13 colonoscopies were performed without
complications [26]. This study was retrospective, and subject to biases relating to recall and
dependence on voluntary reporting. In an other study Cappell and co workers [69] retro‐
spectively examined eight pregnant women undergoing colonoscopies at 10 different medi‐
cal centers. Excluding one elective abortion and one fetal demise unrelated to the
colonoscopy occuring 4 months later, six healthy infants were born. There was no difference
in outcomes based on the trimester during which colonoscopy was performed.
There are several case reports about colonoscopy during pregnancy [80-88], fetal outcomes
after colonoscopy included 8 healthy babies, 2 stillbirth unrelated to the colonoscopy (in
mothers with either metastatic colon cancer or massive lower gastrointestinal hemorrhage
requiring emergency colonic surgery), and one unknown fetal outcome.
Given the limited data on its safety and the potential to cause significant adverse events, co‐
lonoscopy should be reserved to strong indications or life-threatining emergencies during
second trimester. But in case of suspicion of colon cancer, evaluation of colonic mass or co‐
lonic stricture of unknown etiology, for severe uncontrolled colonic hemorrhages, for colon‐
ic pseudoobstruction when the alternative is surgical decompression and when required
before urgent colonic surgery, colonoscopy should be considered even in the first and third
trimester. Colonoscopy should generally be deferred in any trimester of pregnancy until af‐
ter delivery for elective indications, such as surveillance for prior history of colon cancer or
colonic polyps.
7. Therapeutic colonoscopy
Therapeutic colonoscopy includes hemostasis of lower gastrointestinal bleeding, colono‐
scopic polypectomy, and colonic stenting. As mentioned in the hemostasis for NVUGB sec‐
tion,injection therapy with saline, with adrenaline, sclerosants, thrombin, fibrin,
cyanoacrilate, ablative therapy with thermocoagulation, electrocoagulation, photocoagula‐
tion, argon plasma coagulation, and mechanical compression with hemoclips, detachable
snares, graspers, or sutures are used during lower gastrointestinal bleeding [47].
Epinephrine is commonly used to treat gastrointestinal bleeding and achieves hemostasis
through its vasoconstrictive effects. There are numerous studies about the fetal safety of epi‐
nephrine administration during labor which established its fetal safety so it is commonly
added to spinal epidural anesthesia. Although in the report of Briggs and colleagues’ [10],
there was no congenital defect in 35 infants with first trimester in utero exposure of epi‐
nephrine, there is a case report of fatal intracranial hemorrhage in an infant during child‐
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birth after excessive in utero epinephrine [89]. Because of the epinephrine’s α adrenergic
effect of decreasing uterine blood flow, it is a category C during pregnancy and its dosage
should be kept low during pregnancy.
Electrocautery is also another method of providing hemostasis during lower gastrointestinal
bleeding, also used for performing polypectomy or hot biopsy. Using electrocautery to le‐
sions may occasionally be required during pregnancy and has been safely performed with‐
out detectable advers effcts to fetus. However, because amniotic fluid has been
demonstrated to conduct electrical current, externally placed grounding pad should be
placed close to the electrical catheter, devices should use bipolar currents. Polyp removal if
not bleeding, should be postponed after pregnancy [4, 5, 66].
Colonic tattooing is done with Indian ink and methylene blue in nonpregnant patients. Indi‐
an ink has been shown to persist for the entire life of patient. There have ben no reports of
long term complications of Indian ink tattooing. Methylene blue tattooing during pregnancy
is not been studied but there are reports of examination of Metylene blue during amniocent‐
esis and in detection of ruptured membranes. In these reports fetal death, jejunal atresia, is
reported which labels Metylene blue as teratogenic. Although safety of colonic injection is
not studied; its usage should be avoided during pregnancy [66, 90, 91].
8. Enteroscopy
Enteroscopy takes a very long time of procedure with a long time of anesthesia. There is no
case report of enteroscopy during pregnancy, so the fetal safety of enteroscopy could not be
predicted.
9. Video capsule endoscopy
Video capsule endoscopy (VCE) represents a significant advance in the investigation of
small bowel diseases. The main indications are obscure gastrointestinal hemorrhages,
Crohn’s disease, celiac disease, small bowel tumors and polyposis syndromes. The main
contraindications are known or suspected gastrointestinal obstruction, strictures, fistulas,
cardiac pacemakers and swallowing disorders [92]. During pregnancy the growing gravid
uterus pushes and compresses the gastrointestinal tract, and gastrointestinal motility de‐
creases due to inhibition of intestinal smooth muscle by gestational progestin. These effects
raise the theoretical concerns regarding capsule impaction during pregnancy [4,93]. Al‐
though according to the FDA, pregnancy is a relative contraindication for VCE [92]; there is
a report of VCE usage in a young acute bleeding pregnant patient in whom endoscopy and
colonoscopy revealed no lesion other than fresh blood exiting the terninal ileum. On VCE an
actively bleeding jejunal lesion was shown of which pathology was jejunal carcinoid tumor.
Patient and fetus did well after surgery [94]. From this report, it can be concluded that VCE
may be considerable during pregnancy for strong indications, it is not absolutely contraindi‐
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cated during pregnancy. But it is more likely to be incomplete when done during pregnancy
because of slowed intestinal transit time during pregnancy.
9.1. Endoscopic retrograde cholangiopancreatography
Pregnancy is associated with an increased risk of gallstone formation. Fortunately, compli‐
cations due to cholelithiasis, such as cholecystitis, choledocholithiasis and pancreatitis are
relatively uncommon and in many cases can be managed conservatively. However occasion‐
ally patients develop complications related to gallstones that require intervention during
pregnancy. Although there are no precise estimates of the incidence, several reports have
found that biliary tract disease (most commonly cholecystitis) represented one of the most
frequent indications for non-obstetrical surgery during pregnancy [95-99].
A subset of patients requires ERCP, most commonly for choledocholithiasis or presumed
gallstone pancreatitis. Opinions regarding the safety of ERCP during pregnancy differ in
various reports, reflecting the relatively limited data. Major concerns surround issues relat‐
ed to radiation exposure to the fetus and the risk of procedure on pregnancy outcome.
A general principle in the care of the women with an acute biliary tract disorder during
pregnancy is to provide the most conservative management possible with the hope of delay‐
ing intervention until after pregancy or until the second trimester, when surgical interven‐
tion is relatively safer. There are numerous reports about ERCP during pregnancy especially
for the last ten years.
The largest series in the literature included 65 pregnant patients [100]; the most common in‐
dications for ERCP during pregnancy were recurrent biliary colic, abnormal liver function
tests, and a dilated bile duct on ultrasound. Sixty eight ERCP was performed on 65 pregnant
patients, 17 pregnants were in the first trimester, 20 pregnants were in the second trimester
and 31 pregnants were in the third trimester. The median fluoroscopy time was 1.45 mi‐
nutes. Almost all patients underwent a therapeutic procedure. Post ERCP pancreatitis devel‐
oped in 11 patients (16%), none of whom had a severe course. Most patients achieved a term
pregnancy (89%), there were no fetal deaths, perinatal deaths, or evident congenital malfor‐
mations. Only 5 babies (8%) were born prematurely or with low birth weight.
Another series of 23 patients included 20 of whom underwent a therapeutic ERCP while
three underwent a diagnostic ERCP only [101]. One patient developed post ERCP pancreati‐
tis (after each of her three ERCP). There was one spontaneous abortion and one neonatal
death 26 hours after delivery. The neonatal death and post-ERCP pancreatitis were in the
same patient who undergone three ERCPs (twice during the first and one during the third
trimesters) with pancreatic duct stenting for stenosis of pancretaic orifice after a previous
surgical sphincteroplasty.
Shelton et al in a retrospective series of 21 cases of ERCP with sphincterotomy reported suc‐
cessful extraction of stones in 14 women and successful removal of sludge in 7 women.
There was one maternal complication of pancreatitis. There were 17 healthy babies deliv‐
ered at term; One preterm, low birth weight baby, and 3 unknown fetal outcomes [102].
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Another series described long term follow up of 18 pregnant women who underwent biliary
sphincterotomy for common bile duct stones during pregnancy (first trimester 4, second 6,
third 8) [103]. Despite short term complications (one with postsphincterotomy bleedings,
one with mild post ERCP pancreatitis and preterm labor), no long term maternal complica‐
tions were seen after a median of six years (range 1-11 year). Only 11 of the 18 families were
retrospectively contacted; all 11 babies were healthy on follow up at a mean of 6 years post‐
partum. Only one mother had preterm delivery.
Kahaleh et al reported a total of 17 pregnant patients underwent ERCP; of which 15 had ra‐
diation dosimetry measured. Mean fluoroscopy time was 14 seconds (1-48seconds), mean
estimated fetal radiation exposure was 40mrad (1-180mrad). Complications were reported
as; postsphincterotomy bleeding in one patient, which was controlled by placement of he‐
moclip, and post-ERCP pancreatitis in one patient. All infants delivered had Apgar scores of
8 or greater. Thirteen of 15 patients who delivered were contacted, and they confirmed that
their child was in good health. [104].
In an another series of 15 patients, the incidence of complications (7%) was no different than
the rate of complications observed in nonpregnant patients. [105]. There were no serious ad‐
verse outcomes to the fetus or mother.
Different from the aforementioned reports, Farca et al reported a prospective study ≥10 ther‐
apeutic ERCP during pregnancy [106]. In this study a single 10F stent was placed without
sphincterotomy, all patients had uncomplicated pregnancies and delivered healthy infants.
All underwent ERCP with sphincterotomy and stent extraction postpartum; 8 had stones ex‐
tracted. In two patients, the single 10F stent remained in place for 7 and 8 months, respec‐
tively; no one developed cholangitis.
During the ERCP in pregnancy the perceived risk of radiation exposure is much greater
than the actual risk, but a full explanation of these risks to the pregnant patient and her fam‐
ily is more credible if given prior to exposure. Patients should be fully informed, back‐
ground population risks for miscarriage, congenital anomalies, genetic disease, and the
growth restriction are approximately 20, 4, 10 and 10 percent, respectively. Potential radia‐
tion exposure risks to the fetus can be divided into four categories: intrauterine fetal death,
malformations, disturbance of growth and development, mutagenic and carcinogenic ef‐
fects.
Ionizing radiation is measured in special units, rad (radiation absorbed dose) and rem (radi‐
ation equivalent man) and in the international units, gray (Gy) and sievert (Sv)
(1 rad = 1rem = 0.01Gy = 0.01Sv). The avarage person in United States receives about 360
mrem of ionizing radiation annually, of which about 60 mrem comes from man-made sour‐
ces, including medical exposures such as diagnostic radiographs. The rem is a unit used to
measure the effect of radiation on the human body is referred to as the ‘ effective dose
equivalent’. Fetal radiation exposure can result in developmental abnormalities, particularly
if exposure is during the first trimester when organogenesis occurs. High radiation exposure
may result in fetal wastage. Although estimates vary, it is recommended that fetal radiation
exposure not exceed 100mrem during the first trimester [104].
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Data from studies of animals and nuclear bomb survivors suggest that the period of major
organogenesis, between the 8th and 15th weeks of gestation, is the most sensitive for growth
retardation, which may be observed with exposures of 200-250mrem. Exposures greater
than 100mrem occuring later, during neuron development and migration, may be associated
with microcephaly, seizures, decline in mental ability, and childhood cancer [107]. During
the whole of gestation, the maxium permitted dose of ionizing radiation to the fetus is
500rems [108].
Lead shielding should be used to minimize radiation exposure to the uterus. The lead apron
shield must be placed underneath the patient and not draped over the abdomen since the
radiation source is underneath the patient when using the standard fluoroscopy C-arm
[109]. External shielding can not elimineta fetal exposure due to internally scattered radia‐
tion. Even though the fetus can be shielded, efforts should be made to avoid performing
ERCP during the first trimester. While harmful effects of radiation exposure are unlikely to
develop below a certain threshold of radiation dose, the threshold associated with a risk of
childhood cancers such as leucemia is not known precisely.
Though a majority of investigators have reported no immediate complication in newborn,
because of low dose radiation exposure, no one has looked 10-20 years after the exposure,
from that point; ERCP without fluoroscopy is investigated.
ERCP without fluoroscopy has been reported in some studies [102,111] in the last years.
Sharma and Maharshi [110] described a two step procedure with biliary sphincterotomy and
stenting without fluoroscopy or ultrasound (US) asistance as a first step and definitive ERCP
with stone extraction after delivery. In another series [102] it is described as; endoscopist
controls wire –guided cannulation first; then the cannule is not advanced in to the duct un‐
less the endoscopist is confident that the bile duct has been cannulated, as assesssed by the
presence of bile flowing around the wire from the papillary orifice. Once biliary cannulation
is confirmed, a standard wire-guided biliary sphincterotomy is performed using the papillo‐
tome. While the bile is not seen flowing around the guidewire, instead of advancing the
catheter to aspirate fluid, a 5F 2 cm stent is inserted over the wire and the drainage from the
stent is observed. The color of draining fluid is used to assess whether the stent is in the bile
duct or the pancreatic duct. If the stent reveals bile flow, a stent –guided biliary sphincterot‐
omy using a needdle-knife is performed. The stent is removed after biliary sphincterotomy.
Even though the introduction of ERCP without fluoroscopy, ERCP should be avoided for
weak indications such as preoperative cholangiography in patients with a low probability of
having choledocholithiasis. Women of childbearing age should be asked about the possibili‐
ty of pregnancy and a pregnancy test should be ordered based on clinical history. Other
methods of diagnosis that do not involve radiation should be considered, magnetic reso‐
nance cholangiopancreatography (MRCP) can provide diagnostic information for a variety
of hepatobiliary conditions while endoscopic ultrasonography (EUS) is highly sensitive and
spesific for choledocholithiasis. MRCP for the detection of common bile duct stone and sub‐
sequent extraction without using fluoroscopy has been reported in some newly published
case reports. In a study conducted by Oto et al [111], the role of MRCP in the evaluation of
pregnant patients with acute pancreaticobiliary disease is investigated; 18 pregnant patients
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underwent MRCP for the indications of right upper quadrant pain, cholangitis, jaundice and
pancreatitis. Fifteen of the 18 patients were also evaluated with abdominal US. Biliary dilata‐
tion was detected in 8 patients with US, but the cause of biliary dilatation could not be deter‐
mined by US in 7 patients. MRCP demonstrated the etiology in four of these patients
(choledocholithiasis, Mirizzi syndrome, choledochal cysts, and intrahepatic biliary stones)
and excluded obstructive pathology in the other four patients. MRCP was unremarkable in
the 7 patients who had no biliary dilatation on US. Three patients underwent only MRCP;
two had choledocholithiasis, and one had cholelithiasis and pancreatitis. While this study
suggests that MRCP may be very helpful diagnostically for acute pancreatobiliary disease in
the pregnant population, this study does not give any information about the fetal outcomes,
including the incidence of congenital amlformations after MRCP during pregnancy.
So, in the case of choledocholithiasis, biliary pancreatitis, cholangitis and findings of coledo‐
chal dilatation on abdomianl US with abnormal serum liver function tests and known gall‐
stones, ERCP with / without fluoroscopy should be made.
9.2. Electrocautery and hemostasis
Using cutting and cauterizing current to lesions may occasioanlly be required during preg‐
nancy and has been safely performed without detectable adverse consequences to the devel‐
oping fetus. However, because amniotic fluid has been demonstrated to conduct electrical
current [112], a number of precautions are appropriate. These include ensuring that the ex‐
ternally placed graunding pad is placed close to the interventional electrical catheter so that
the uterus does not lie between them. Devices using only bipolar currents should be used to
minimize this risk of ‘stray’ currents going through the fetus. Electrocautery is relatively
safe when used for sphincterotomy and hemostasis[2,5].
Epinephrine is category C drug during pregnancy and causes a decrease in uterine blood
flow. Its safety, when used as an endoscopic injectant, has not been studied, although, when
given in low dose combinations for analgesia, it is safe. Its use for hemostasis should balance
the benefits with the potential risks [2].
10. Endoscopic ultrasonography
Endoscopic ultrasonography (EUS) is a widely accepted modality for the diagnosis of gas‐
trointestinal and pancreatobiliary diseases. EUS has been shown to reduce unnecessary in‐
terventions in patients with low or moderate probabilities for choledocholithiasis. It is a safe
alternative to fluoroscopy for the evaluation of biliary disorders during pregnancy. Howev‐
er, there are only case reports on EUS for pregnant patients in the literature. The largest ser‐
ies consist of 6 cases of EUS performed for suspected choledocholithiasis in pregnant
patients [102]. EUS findings revealed choledocholithiasis in two patients, biliary sludge in
two patients and nonsignificant findings in two patients.
All six patients were underwent ERCP after EUS, there were no maternal complications. Fe‐
tal outcome was favorable for 5 infants but one infant outcome was unknown. In another
Endoscopy338
report, EUS was performed for acute pancreatitis of unknown etiology in 3 pregnant pa‐
tients. Biliary pancreatitis without common bile duct stones found in 2 patients and pancrea‐
titis due to unspecified pancreatic anomaly was found in one pregnant patient. There were
no reported maternal complications in this study with 2 healthy infants but one fetal death
10 weeks after EUS probably due to recurrent cholangitis [113].
One may argue that EUS will prolong the overall time for a procedure. However, when EUS
is normal, ERCP interventions can be avoided. In addition, EUS may provide other useful
information. In experienced hands, the added time for EUS can be only a few minutes. So
further studies are required to assess the role of EUS in the management of pregnant pa‐
tients. However, it would seem acceptable to perform EUS when choledocholithiasis is a
possible but unproven diagnosis and MRCP is an undesirable alternative.
11. Endoscopic spyscopy
The SpyGlass system is a recently developed system for performing cholangioscopy, pan‐
creatoscopy. The main advantage over standard ERCP is that with the SpyGlass system the
scope can be inserted directly into the bile duct and the pathology can be directly visualized,
rather than using radiographs to visualize the bile ducts. This direct visualization allows the
endoscopists to obtain a targetted biopsy, if needed, or to use electrohydraulic lithotripsy to
crush stones under direct vision. This technique has been applied to 7 pregnant patients in
the literature, five patients underwent choledochoscopy using spyscopy after ERCP, sphinc‐
terotomy, and balon sweeps; this procedure confirmed the removal of all choledochal stones
in those patients. In one patient this technique is used to show residual 2 mm common bile
duct stones after balon sweeping at ERCP, and in the remainig patient it has been used to
show the sludge coming from the cystic duct. Choledochoscopy produced no maternal com‐
plications in those reports. This technique allows for the limitation or elimination of ionizing
radiation through direct intraductal visualization and stone clearence confirmation. The di‐
agnostic and therapeutic capability of ERCP is increased in a manner that contributes to pa‐
tient safety and hopefully better maternal and fetal outcomes. So more studies are needed of
this technique during pregnancy to asses the fetal outcomes [4, 114-116].
12. Endoscopic cystogastrostomy
Endoscopic cystogastrostomy with or without endosonographic guidance for drainage of
pseudocyst has been demostrated to be an acceptable alternative to radiologic or surgical
drainage. For the pregnant patient who has a pancreatic pseudocyst, this technique would
be ideal because it would eliminate the risk of radiation incurred by a radiologic drainage
and would involve less risk to the fetus than an intraabdominal surgical procedure. There
are only two cases of endoscopic cystogastrostomy procedure applied to pregnant patients.
In one patient it was successful; the pseudocyst was punctured percutaneously under con‐
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ventional ultrasound guidance, than it is aspirated and filled with contrast agent. Then en‐
doscopically a cystogastrostomy was created and a stent was inserted. The patient got well
and gave birth to a healthy infant. In the second patient unfortunately the stent was migrat‐
ed making the procedure partially unsuccessful, but with other techniques patient again got
well and gave birth to a healthy infant too. So according to these two cases endoscopic cys‐
togastrostomy is still a little bit experimental during pregnancy, it should be considered in
pregnants who have symptomatic pseudocysts and cannot delay the procedure until deliv‐
ery [4,29,116-118].
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